Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage
Understanding which patients will respond to FOLFIRINOX therapy is important for clinical outcome. Here, the authors show that the MIR1307 is increased pancreatic cancer cell lines and inhibition of the microRNA sensitises cells to treatment.’ stratifying patients to achieve the best clinical outcom...
Guardado en:
Autores principales: | Pietro Carotenuto, Francesco Amato, Andrea Lampis, Colin Rae, Somaieh Hedayat, Maria C. Previdi, Domenico Zito, Maya Raj, Vincenza Guzzardo, Francesco Sclafani, Andrea Lanese, Claudia Parisi, Caterina Vicentini, Ian Said-Huntingford, Jens C. Hahne, Albert Hallsworth, Vladimir Kirkin, Kate Young, Ruwaida Begum, Andrew Wotherspoon, Kyriakos Kouvelakis, Sergio Xavier Azevedo, Vasiliki Michalarea, Rosie Upstill-Goddard, Sheela Rao, David Watkins, Naureen Starling, Anguraj Sadanandam, David K. Chang, Andrew V. Biankin, Nigel B. Jamieson, Aldo Scarpa, David Cunningham, Ian Chau, Paul Workman, Matteo Fassan, Nicola Valeri, Chiara Braconi |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a029501cd4ea4989bf6d137ae286835e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer
por: Francesco Sclafani, et al.
Publicado: (2018) -
The synergistic effect of Canady Helios cold atmospheric plasma and a FOLFIRINOX regimen for the treatment of cholangiocarcinoma in vitro
por: Olivia Jones, et al.
Publicado: (2021) -
The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis
por: Hongxuan Tong, et al.
Publicado: (2018) -
Phase I Dose-Escalation Trial of an Innovative Chemotherapy Regimen Combining a Fractionated Dose of Irinotecan Plus Bevacizumab, Oxaliplatin, 5-Fluorouracil, and Folinic Acid (bFOLFIRINOX-3) in Chemorefractory Metastatic Colorectal Cancer
por: Hélène Bellio, et al.
Publicado: (2021) -
Gemcitabine plus Nab-paclitaxel as a second-line treatment following FOLFIRINOX failure in advanced pancreatic cancer: a multicenter, single-arm, open-label, phase 2 trial
por: Gunn Huh, et al.
Publicado: (2021)